Stockscreener 앱 받기
14.77
1.61%
0.21
Rxsight Inc 주식(RXST)의 최신 뉴스
Russell Investments Group Ltd. Sells 94,412 Shares of RxSight, Inc. (NASDAQ:RXST) - Defense World
JPMorgan Chase & Co. Reduces Stake in RxSight, Inc. (NASDAQ:RXST) - Defense World
RxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of “Hold” by Brokerages - Defense World
RxSight Inc [RXST] Records 50-Day SMA of $23.43 - knoxdaily.com
What Does RxSight, Inc.'s (NASDAQ:RXST) Share Price Indicate? - Yahoo
RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
RxSight, Leading Eye Surgery Tech Company, Sets Q1 2025 Earnings Release Date - Stock Titan
LPL Financial LLC Boosts Holdings in RxSight, Inc. (NASDAQ:RXST) - Defense World
Geode Capital Management LLC Has $28.57 Million Stock Position in RxSight, Inc. (NASDAQ:RXST) - Defense World
Piper Sandler Initiates Coverage of RxSight (RXST) with Neutral Recommendation - Nasdaq
This Aurora Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Piper Sandler Initiates RxSight at Neutral With $18 Price Target - marketscreener.com
Piper Sandler Begins Coverage of RxSight (RXST) with Neutral Rat - GuruFocus
Piper Sandler sets RxSight stock target at $18, stays neutral By Investing.com - Investing.com South Africa
Piper Sandler sets RxSight stock target at $18, stays neutral - Investing.com
Piper Sandler Starts RxSight Inc. (RXST) at Neutral - StreetInsider
RxSight price target lowered to $17 from $22 at Wells Fargo - MSN
RxSight plunges after guidance cut; BofA downgrades - MSN
RxSight stock plunges to 52-week low at $14.24 amid market challenges By Investing.com - Investing.com South Africa
RxSight stock plunges to 52-week low at $14.24 amid market challenges - Investing.com
RxSight, Inc. (NASDAQ:RXST) Position Lifted by Vanguard Group Inc. - The AM Reporter
UBS cuts RxSight stock rating to neutral, slashes price target to $16 By Investing.com - Investing.com South Africa
RxSight downgraded at UBS after Q1 miss and guidance cut - MSN
RxSight stock downgraded at UBS on guidance cut (RXST:NASDAQ) - Seeking Alpha
Needham Cuts Price Target on RxSight to $22 From $43, Keeps Buy Rating - MarketScreener
UBS Downgrades RxSight to Neutral From Buy, Cuts Price Target to $16 From $45 - MarketScreener
UBS cuts RxSight stock rating to neutral, slashes price target to $16 - Investing.com Australia
UBS Downgrades RxSight Inc. (RXST) to Neutral - StreetInsider
RxSight at Needham Conference: Strategic Adjustments Amid Market Challenges By Investing.com - Investing.com Canada
Analysts Are Neutral on Top Healthcare Stocks: RxSight (RXST), Johnson & Johnson (JNJ) - The Globe and Mail
Needham & Company LLC Reiterates “Buy” Rating for RxSight (NASDAQ:RXST) - Defense World
Rxsight adjusts 2025 revenue guidance to $160M-$175M amid premium IOL market challenges - MSN
Midday Stock Roundup: Masimo, Virgin Galactic an Others Take Dives - Orange County Business Journal
JP Morgan downgrades RxSight on market, competitive pressures - Investing.com
JPMorgan Downgrades RxSight to Underweight From Overweight, Adjusts Price Target to $17 From $40 - MarketScreener
Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings) - Benzinga
RxSight’s preliminary Q1 2025 revenue expected to increase 28% - Medical Buyer
American Express, Rxsight, Vertiv Holdings - TradingView
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ... By GuruFocus - Investing.com Canada
JPMorgan Double Downgrades RxSight Inc. (RXST) to Underweight - StreetInsider
RxSight Faces Market Challenges As Revenue Guidance Drops - Finimize
RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) - Seeking Alpha
JPMorgan cuts RxSight stock rating, slashes price target to $17 By Investing.com - Investing.com South Africa
JPMorgan cuts RxSight stock rating, slashes price target to $17 - Investing.com
RxSight stock plunges to 52-week low at $15.84 amid market challenges By Investing.com - Investing.com South Africa
RxSight stock plunges to 52-week low at $15.84 amid market challenges - Investing.com India
RxSight downgraded to Underweight from Overweight at JPMorgan - TipRanks
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips By Investing.com - Investing.com South Africa
RxSight Analyst Flags Growth Slowdown As Revised Outlook Misses Expectations - Benzinga
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
RxSight plunges after guidance cut - MSN
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock - Yahoo Finance
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of Americ - GuruFocus
BTIG cuts RxSight stock price target to $28 from $44 By Investing.com - Investing.com Australia
0.45%
0.28%
자본화:
|
볼륨(24시간):